A randomized crossover trial of topical lidocaine-prilocaine cream versus lidocaine cream for analgesia during venipuncture

DOI Web Site 参考文献13件 オープンアクセス
  • Michihata Nobuaki
    Medical Support Center for the Japan Environment and Children’s Study, National Center for Child Health and Development Center for Postgraduate Education and Training, National Center for Child Health and Development
  • Yamamoto-Hanada Kiwako
    Medical Support Center for the Japan Environment and Children’s Study, National Center for Child Health and Development Allergy Center, National Center for Child Health and Development
  • Futamura Masaki
    Allergy Center, National Center for Child Health and Development
  • Kitazawa Hiroshi
    Medical Support Center for the Japan Environment and Children’s Study, National Center for Child Health and Development Allergy Center, National Center for Child Health and Development
  • Ishiguro Akira
    Center for Postgraduate Education and Training, National Center for Child Health and Development
  • Ohya Yukihiro
    Medical Support Center for the Japan Environment and Children’s Study, National Center for Child Health and Development Allergy Center, National Center for Child Health and Development

この論文をさがす

説明

<p>BACKGROUND</p><p>Preparations of 2.5% lidocaine plus 2.5% prilocaine cream (trade name EMLA® cream) or 5% lidocaine cream (trade name LMX5® cream) are used for local anesthesia. To our knowledge, no study has directly compared the analgesic effects for venipuncture between EMLA® cream and LMX5® cream. We conducted a double-blinded randomized crossover trial to evaluate the analgesic effects of these two creams in healthy adults using a visual analogue scale (VAS).</p><p>METHODS</p><p>This crossover trial enrolled 24 healthy adult participants randomly assigned to 4 groups by combining 2 formulations of anesthetics and different left-right arm-treatment protocols. The primary outcome was each subject’s VAS score (range 0 to 100) for pain during blood sampling. The secondary outcomes were blood sampling site, blood sampling volume, blood sampling frequency, and occurrence of side effects. We conducted a multivariate regression analysis for the VAS score after adjusting for participants’ background characteristics while also adjusting for clustering of arm-treatment protocols within individuals using a generalized estimating equation.</p><p>RESULTS</p><p>There were no significant differences between EMLA® and LMX5® cream after adjusting for participants’ background characteristics, including age and sex (difference: 2.83; 95% confidence interval: −11.25 to 16.92; P value: 0.693). There were also no marked differences in secondary outcomes between EMLA® cream and LMX5® cream. No adverse reactions that could be clinically problematic were observed with either cream.</p><p>CONCLUSION</p><p>This randomized crossover trial showed that there was no significant analgesic difference between EMLA® cream and LMX5® cream. Both creams were effective without clinically serious side effects.</p><p> </p><p>The registration number is UMIN000011463.</p><p>The registry website is UMIN (http://www.umin.ac.jp/ctr/index.htm).</p>

収録刊行物

参考文献 (13)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ